Cargando…
Non-invasive Markers of Liver Fibrosis: Adjuncts or Alternatives to Liver Biopsy?
Liver fibrosis reflects sustained liver injury often from multiple, simultaneous factors. Whilst the presence of mild fibrosis on biopsy can be a reassuring finding, the identification of advanced fibrosis is critical to the management of patients with chronic liver disease. This necessity has lead...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4913110/ https://www.ncbi.nlm.nih.gov/pubmed/27378924 http://dx.doi.org/10.3389/fphar.2016.00159 |
_version_ | 1782438368013975552 |
---|---|
author | Chin, Jun L. Pavlides, Michael Moolla, Ahmad Ryan, John D. |
author_facet | Chin, Jun L. Pavlides, Michael Moolla, Ahmad Ryan, John D. |
author_sort | Chin, Jun L. |
collection | PubMed |
description | Liver fibrosis reflects sustained liver injury often from multiple, simultaneous factors. Whilst the presence of mild fibrosis on biopsy can be a reassuring finding, the identification of advanced fibrosis is critical to the management of patients with chronic liver disease. This necessity has lead to a reliance on liver biopsy which itself is an imperfect test and poorly accepted by patients. The development of robust tools to non-invasively assess liver fibrosis has dramatically enhanced clinical decision making in patients with chronic liver disease, allowing a rapid and informed judgment of disease stage and prognosis. Should a liver biopsy be required, the appropriateness is clearer and the diagnostic yield is greater with the use of these adjuncts. While a number of non-invasive liver fibrosis markers are now used in routine practice, a steady stream of innovative approaches exists. With improvement in the reliability, reproducibility and feasibility of these markers, their potential role in disease management is increasing. Moreover, their adoption into clinical trials as outcome measures reflects their validity and dynamic nature. This review will summarize and appraise the current and novel non-invasive markers of liver fibrosis, both blood and imaging based, and look at their prospective application in everyday clinical care. |
format | Online Article Text |
id | pubmed-4913110 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-49131102016-07-04 Non-invasive Markers of Liver Fibrosis: Adjuncts or Alternatives to Liver Biopsy? Chin, Jun L. Pavlides, Michael Moolla, Ahmad Ryan, John D. Front Pharmacol Pharmacology Liver fibrosis reflects sustained liver injury often from multiple, simultaneous factors. Whilst the presence of mild fibrosis on biopsy can be a reassuring finding, the identification of advanced fibrosis is critical to the management of patients with chronic liver disease. This necessity has lead to a reliance on liver biopsy which itself is an imperfect test and poorly accepted by patients. The development of robust tools to non-invasively assess liver fibrosis has dramatically enhanced clinical decision making in patients with chronic liver disease, allowing a rapid and informed judgment of disease stage and prognosis. Should a liver biopsy be required, the appropriateness is clearer and the diagnostic yield is greater with the use of these adjuncts. While a number of non-invasive liver fibrosis markers are now used in routine practice, a steady stream of innovative approaches exists. With improvement in the reliability, reproducibility and feasibility of these markers, their potential role in disease management is increasing. Moreover, their adoption into clinical trials as outcome measures reflects their validity and dynamic nature. This review will summarize and appraise the current and novel non-invasive markers of liver fibrosis, both blood and imaging based, and look at their prospective application in everyday clinical care. Frontiers Media S.A. 2016-06-20 /pmc/articles/PMC4913110/ /pubmed/27378924 http://dx.doi.org/10.3389/fphar.2016.00159 Text en Copyright © 2016 Chin, Pavlides, Moolla and Ryan. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Chin, Jun L. Pavlides, Michael Moolla, Ahmad Ryan, John D. Non-invasive Markers of Liver Fibrosis: Adjuncts or Alternatives to Liver Biopsy? |
title | Non-invasive Markers of Liver Fibrosis: Adjuncts or Alternatives to Liver Biopsy? |
title_full | Non-invasive Markers of Liver Fibrosis: Adjuncts or Alternatives to Liver Biopsy? |
title_fullStr | Non-invasive Markers of Liver Fibrosis: Adjuncts or Alternatives to Liver Biopsy? |
title_full_unstemmed | Non-invasive Markers of Liver Fibrosis: Adjuncts or Alternatives to Liver Biopsy? |
title_short | Non-invasive Markers of Liver Fibrosis: Adjuncts or Alternatives to Liver Biopsy? |
title_sort | non-invasive markers of liver fibrosis: adjuncts or alternatives to liver biopsy? |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4913110/ https://www.ncbi.nlm.nih.gov/pubmed/27378924 http://dx.doi.org/10.3389/fphar.2016.00159 |
work_keys_str_mv | AT chinjunl noninvasivemarkersofliverfibrosisadjunctsoralternativestoliverbiopsy AT pavlidesmichael noninvasivemarkersofliverfibrosisadjunctsoralternativestoliverbiopsy AT moollaahmad noninvasivemarkersofliverfibrosisadjunctsoralternativestoliverbiopsy AT ryanjohnd noninvasivemarkersofliverfibrosisadjunctsoralternativestoliverbiopsy |